Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 3

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 3
---
 engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda's business is grouped into six key business areas: Gastroenterology (“GI”), Rare Diseases, Plasma-Derived Therapies (“PDT”), Oncology, Vaccines and Neuroscience. Our R&D efforts focus on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience, and Oncology. We also make targeted R&D investments in PDT. We focus on developing innovative medicines that make a difference in people’s lives by advancing the frontier of new treatment options and leveraging our collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. We focus on high unmet medical needs, both in rare and more prevalent conditions, to deliver high-quality medicines to patients and communities as quickly as possible. We have a presence in approximately 80 countries and regions, a network of manufacturing sites around the world, and major research centers in Japan and the United States. Commercially, we have a very significant presence in the United States, Japan, Europe, as well as a fast-growing business in China. We have also accelerated our focus on data, digital and technology to make our business operations more effective and efficient, increase innovation and better serve our stakeholders.

(ii) Consolidated Financial Results (April 1, 2024 to March 31, 2025)

| 2024                                                                             |     | For the fiscal year ended 
 March 31,                 |     | 2025 |          |     | Amount of Change |     |          |     | AER      
 % Change |     |        |     | % Change |     |       |   | CER |     |       |   |     | Billion JPY or percentage |
|:---------------------------------------------------------------------------------|:----|:--------------------------|:----|:-----|---------:|:----|:-----------------|:----|---------:|:----|:---------|:----|-------:|:----|:---------|:----|------:|:--|:----|:----|------:|:--|:----|:--------------------------|
| Revenue                                                                          |     |                           |     |      |  4,263.8 |     |                  |     |  4,581.6 |     |          |     |  317.8 |     |          |     |   7.5 | % |     |     |   2.9 | % |